Observation

Abnormal ghrelin secretion in new onset childhood Type 1 diabetes
To the Editor: Ghrelin is a new circulating peptide hormone produced mainly by the stomach [1] and involved in the regulation of feeding behaviour and energy homeostasis [2] . The concentrations of ghrelin are low in obese subjects [3, 4] and high in anorexic subjects [5] . In normal subjects the ghrelin secretion is stimulated by fasting and reduced by feeding [6] and by oral glucose load [4] . The mechanism of hormone release from the A-like ghrelin-producing cells [7] of the gastric mucosa is not yet known.
We examined ghrelin concentrations in 22 children; 11 boys and 11 girls, age 16±3.6 years (mean±SD), BMI 18.0± 5.2 kg/m 2 (mean±SD) with a new onset of Type 1 diabetes. Blood samples were obtained at diagnosis before and after 10 days of insulin treatment, blood glucose 24.6±8.7 and 6.6± 3.0 mmol/l, respectively, and in conjunction with meal tests, carried out in 15 and 20 of the cases at 3 and 9 months after the start of insulin therapy, respectively. At meal tests the patients were fasting over night and had received no insulin in the morning. Then they had a standardised breakfast (20% of their daily energy intake, containing 33% fat, 50% carbohydrates and 17% proteins) and blood was drawn at time zero and after 30, 60, 90, 120, and 150 min. Ghrelin was measured in the samples taken just before the test and when C-peptide reached its maximum. Ghrelin was determined in serum using a radioimmunoassay (Phoenix Pharmaceuticals, Belmont, Calif., USA), which uses 125 I-labelled bioactive ghrelin as a tracer and a polyclonal antibody raised in rabbits against the fulllength, octanoylated human ghrelin. Intra-assay and inter-assay coefficients of variance were 5.3% and 13.6%, respectively. Statistical significance was evaluated by Mann-Whitney U test and Wilcoxon signed rank test. The study was approved by the Research Ethics Committee at the Faculty of Health Sciences, Linköping.
Ghrelin concentrations at diagnosis prior to insulin treatment and after 10 days were 48.9 ±24.6 and 74.3±61.5 pmol/l (mean±SD), respectively (p=0.007). Blood glucose and C-peptide values increased during the meal tests ( Fig. 1) , whereas no changes in serum ghrelin were observed; the ghrelin values before and after test meals were 61.9±43.9 and 59.1±32.2 pmol/l at 3 months, and 93.4±72.4 and 81.9±55.5 pmol/l at 9 months, respectively. In a group of ten healthy children, five boys and five girls with a mean age of 12 years, the fasting serum ghrelin concentration was 108.5±32.5 pmol/l, (p=0.001), compared with the ghrelin values of the patients prior to insulin treatment.
To our knowledge, there are no previous reports on circulating ghrelin concentrations in patients with Type 1 diabetes. Patients with Type 2 diabetes were included in a previous study [6] which examined ghrelin concentrations in lean, normal weight and obese non-diabetic subjects and included observations on 42 subjects with Type 2 diabetes, 8 of whom were treated with diet alone, 22 with oral hypoglycaemic agents and 8 with insulin. Fasting plasma ghrelin concentration was negatively correlated with BMI in both subjects with Type 2 diabetes and those without. The plasma ghrelin concentrations of normal subjects decreased significantly after oral glucose administration, and a similar response was observed in patients with Type 2 diabetes after a meal tolerance test, reaching a nadir of 69% of the basal level after the meal. Similarly, a suppressive effect of a mixed liquid meal or oral glucose on serum ghrelin values in healthy human subjects was noted [8] . In contrast, we found that the children with Type 1 diabetes did not respond to meal tests with suppression of ghrelin values. One could speculate that ghrelin concentrations are low at di- Response to meal tests, carried out at 3 (n=15) and 9 (n=20) months after starting insulin treatment in childhood Type 1 diabetes. Results (mean ± SEM) from pre-and postmeal blood samples at each time point; ***p<0.0001; NS, nonsignificant agnosis before the first insulin injection because of the insulinopaenia, high blood glucose load and deranged lipid metabolism, and then increases at later follow up with more normal blood glucose and metabolic control.
In conclusion, childhood Type 1 diabetes seems to be associated with abnormalities in ghrelin secretion. The circulating concentrations are low prior to insulin treatment and responses to meal tests are absent. As ghrelin is involved in the regulation of feeding behaviour and energy homeostasis, abnormalities in ghrelin secretion may play a role for the metabolic balance in diabetic children. To the Editor: Type 1 diabetes is an autoimmune disease caused by selective destruction of the insulin-producing beta cells. Both, genetic predisposition and non-genetic, environmental factors, are believed to be involved in inducing Type 1 diabetes [1] . Several mechanisms by which environmental factors, such as pathogenic agents, might be involved in the development of autoimmune diseases have been proposed. One mechanism, "molecular mimicry"-has become popular in explaining the loss of tolerance in autoimmune diseases. In this hypothesis an immune response mounted against a foreign determinant crossreacts with a host determinant, leading to inflammation and autoimmune destruction of the host tissue or organ. Similarities in sequence, structure or epitope-sharing between pathogens and host antigens have all been put forward as mechanisms which might drive this phenomenon [2, 3] . An association of infection with a particular pathogen and the induction of autoimmunity have been shown for reactive arthritis (RA), Guillain-Barre syndrome (GBS) and multiple sclerosis (MS) [4, 5, 6, 7] . Bacteria as potent immunogens express many factors that can act as immune stimulants. A multifunctional receptor CD14, interacts with several cell-wall components of gram-positive and gramnegative bacteria including lipopolysaccharide (LPS) and peptidoglycan. Recent studies suggest that CD14 is not only able to act as an immune receptor for "non-self" components such as LPS but it is also able to interact with "self" components (apoptotic cells) [8] . Since CD14 plays a key role in the regulation of the inflammatory cascade and since it also interacts with "self" components, perhaps there is an involvement of CD14 in the development of Type 1 diabetes in the non-obese diabetic (NOD) mouse model. To this end we have used classic genetic procedures to generate a NOD congenic line carrying a targeted deletion of the CD14 gene.
Our experiments where carried out in accordance with the rules for animal care of the Ministry of Nutrition, Agriculture and Forestry of the German government and were approved by the Institution's animal care and use committee. CD14-deficient male mice (backcrossed into the C57BL/6J, a gift from Dr. D. Golenbock (Boston Medical and Boston University School of Medicine, Boston, Mass., USA) were crossed with NOD female mice (M&B A/S, Denmark) to produce F1 hybrids which were backcrossed onto NOD background. In each backcross generation mice which were heterozygous for CD14 deficiency (CD14+/−) were selected using primers for CD14 (F: 5′-CCAAGTTTTAGC GCTGCGTAAC-3′; R: 5′-GCCA
